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Martin Reck, MD, PhD,** and Claus-Peter Schneider, MD††
Introduction: Safety of Avastin in Lung (MO19390) was an inter-
national, open-label, single-arm study, which assessed the safety and
efficacy of first-line bevacizumab (Avastin®) in combination with
standard chemotherapy in patients (n  2212) with advanced or
recurrent non-small cell lung cancer (NSCLC). A preplanned sub-
group analysis was performed to examine these outcomes in elderly
patients older than 65 years.
Methods: Eligible patients with nonsquamous NSCLC received up
to six cycles of bevacizumab (7.5 or 15 mg/kg) plus any standard of
care chemotherapy. Patients who did not experience disease pro-
gression after induction therapy continued bevacizumab therapy
until disease progression or unacceptable toxicity. The primary end
point was safety; secondary end points included time to disease
progression (TTP) and overall survival (OS).
Results: Data were evaluated for 623 patients older than 65 years
(mean age 70.6). The majority were Whites (86.2%) with stage IV
disease (79.7%) and had adenocarcinoma (83.5%). The incidence of
adverse events (AEs) of special interest was similar for elderly and
younger patients (any grade bleeding 38.2% versus 38.3%; any
grade hypertension 33.1% versus 30.6%; any grade proteinuria
33.4% versus 29.3%). Most AEs were grade less than or equal to 2.
Serious AEs were reported in 45.3 and 34.7% of elderly and younger
patients, respectively. Median OS was similar in elderly and
younger patients (14.6 months in both age groups), as were TTP (8.2
versus 7.6 months), response rate (49.3% versus 52.4%), and disease
control rate (89.3% versus 88.4%). Similar results were seen in a
post hoc comparison of the older than 70 years and 70 years or
younger subgroups: TTP was 8.6 months versus 7.7 months, respec-
tively; OS was 14.6 months in both subgroups; response rate was
49% and 52%, respectively; incidence of AEs of special interest was
comparable.
Conclusion: Patients older than 65 years with nonsquamous
NSCLC derive a similar clinical benefit from first-line bevacizumab-
based therapy as their younger counterparts and do not experience
increased toxicity.
Key Words: Bevacizumab, Vascular endothelial growth factor,
Safety, Elderly, Non-small cell lung cancer (NSCLC).
(J Thorac Oncol. 2012;7: 203–211)
Platinum doublet chemotherapy has been established asstandard first-line therapy for patients with advanced
non-small cell lung cancer (NSCLC) on the basis of a
meta-analysis and multiple phase III clinical trials,1 demon-
strating that platinum-containing chemotherapy regimens are
superior to best supportive care and are associated with
median survivals of 8 to 11 months and 1-year survivals of
30% to 45%.1–7 However, although it is estimated that about
50% of newly diagnosed cases of NSCLC occur in patients
older than 65 years,8 there has been an historical reluctance to
use platinum compounds in elderly patients because of con-
cerns about toxicity and tolerability.9–11
Treatment restrictions for elderly patients are often
based on the assumption that accumulated comorbidities will
have led to physiological changes that compromise drug
pharmacokinetics and metabolism. Consequently, elderly pa-
tients may receive less chemotherapy and are less likely to be
enrolled in clinical trials. However, aging is a highly individ-
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ual process and the changes that occur cannot be predicted on
the basis of chronological age alone. The Elderly Lung
Cancer Vinorelbine Italian Study12 and subsequent Multi-
center Italian Lung Cancer in the Elderly Study13 were the
first trials to show the benefits of single-agent gemcitabine or
vinorelbine over best supportive care, in the elderly age
group. Although until recently no prospective phase III trials
investigating platinum-based chemotherapy had been con-
ducted specifically involving elderly patients, retrospective
age-specific subgroup analyses of several phase III trials
indicated that clinical outcome does not differ significantly
between age groups.14–18 In 2010, Quoix et al.19 presented
data from the first prospective, randomized phase III study in
patients with NSCLC aged 70 to 89 years with Eastern
Cooperative Oncology Group performance status (ECOG PS)
0 to 2. Paclitaxel-carboplatin doublet was shown to signifi-
cantly extend survival compared with standard single-agent
therapy while maintaining an acceptable side effect profile.
Thus, there is substantial body of data indicating that chemo-
therapy provides meaningful clinical benefits in fit elderly
patients with advanced NSCLC.
Bevacizumab is the first and only antivascular endothe-
lial growth factor therapy for the first-line treatment of
nonsquamous NSCLC approved for use in North America
(US Food and Drug Administration and Health Canada) and
Europe (European Medicines Agency). The phase III ECOG
4599 study20 demonstrated a 2-month difference in median
survival with the addition of bevacizumab to carboplatin-
paclitaxel (hazard ratio 0.79; p  0.003), leading to its
approval in the United States and the general acceptance of
this regimen as the standard of care. Subsequently, the results
of the Avastin in Lung (AVAiL) study of first-line bevaci-
zumab with cisplatin plus gemcitabine demonstrated a sig-
nificant improvement in progression-free survival (PFS);
overall survival (OS) was numerically longer with the addi-
tion of bevacizumab although the difference was not statis-
tically significant.21,22
The phase IV Safety of Avastin in Lung (SAiL
[MO19390]) study was conducted to determine the safety and
efficacy of first-line bevacizumab combined with a range of
standard chemotherapy regimens in a broad patient popula-
tion.23 Here, we report a preplanned analysis of the SAiL
study undertaken to determine the safety profile and clinical
benefits of this therapy in elderly patients with advanced or
recurrent nonsquamous NSCLC. Elderly was defined as age
older than 65 years, which has previously been reported in the
oncology literature,24 and is defined in the National Compre-
hensive Cancer Network Senior Adult Oncology guidelines
as an accepted societal age cutoff for the definition of el-
derly.25 Use of an older cutoff age, such as 70 years, is
increasingly common, however, and an additional post hoc
analysis was conducted using this cutoff.
PATIENTS AND METHODS
Study Design and Objectives
The SAiL study was a phase IV, open-label, multi-
center, single-arm study conducted in a general patient pop-
ulation, including elderly patients, those receiving concomi-
tant medications, and those with ECOG PS 2. Known central
nervous system (CNS) metastases were not allowed, but
patients were not screened for subclinical CNS metastases
before enrolment. The primary objective was to assess the
safety profile of bevacizumab in combination with chemo-
therapy as first-line treatment of advanced or recurrent nons-
quamous NSCLC. Secondary objectives included assessment
of efficacy of these combinations as measured by time to
disease progression (TTP) and OS and assessment of safety in
patients who developed CNS metastases during and up to 6
months after the treatment period. Overall response rates
(ORR) and disease control rates (DCR; ORR plus stable
disease) were assessed according to the treating physicians’
routine clinical practice. The study protocol did not specify
an evaluation method or the frequency of assessment; this
was done according to the local practice standard of care. No
centralized independent assessment of response was done.
Patients
Full details of the inclusion and exclusion criteria have
been published previously.23 A total of 2212 patients were
recruited between August 2006 and June 2008 from 40
countries across six continents. Eligible patients had histo-
logically or cytologically documented, inoperable, locally
advanced (stage IIIB with supraclavicular lymph node me-
tastases or malignant pleural or pericardial effusion), meta-
static (stage IV), or recurrent nonsquamous NSCLC.
Treatment
Patients received up to six cycles of bevacizumab (7.5
or 15 mg/kg on day 1 and then every 3 weeks) in combination
with standard-of-care first-line chemotherapy (bevacizumab
dose and chemotherapy regimen at investigators’ discretion).
The study protocol permitted the use of nonplatinum doublets
and single-agent chemotherapy regimens if the center had
experience with an established regimen, or for patients who
were elderly or had an ECOG PS of 2. After a maximum of
six cycles of chemotherapy plus bevacizumab, nonprogress-
ing patients continued to receive bevacizumab therapy alone
until disease progression or unacceptable toxicity.
Assessments
All reported serious adverse events (SAEs) and non-
SAEs associated with bevacizumab or chemotherapy were
used to assess the safety profile of the bevacizumab combi-
nations. The incidence of adverse events (AEs) of special
interest (AESIs) for bevacizumab, namely hypertension, pro-
teinuria, wound-healing complications, gastrointestinal per-
forations, arterial and venous thromboembolic events, he-
moptysis, CNS bleeding, other hemorrhages, and congestive
heart failure, was also assessed. AEs were graded according
to National Cancer Institute Common Terminology Criteria
for Adverse Events version 3. All AEs occurring up to 28
days after the last bevacizumab infusion were recorded.
AESIs were reported up to 6 months after the last bevaci-
zumab infusion, and SAEs associated with bevacizumab were
reported for the duration of the study. Information on existing
medical conditions other than NSCLC was also recorded, as
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were concomitant medications at baseline. Disease response
was determined according to standard clinical practice.
Statistical Analysis
The intention to treat (ITT) population (n  2212) was
the primary analysis population; it included all patients with
at least one valid postbaseline tumor assessment. All demo-
graphics and safety and efficacy analyses were based on the
ITT population. The data reported here are from preplanned
analyses of safety and efficacy data recorded for patients
older than 65 years or 65 years or younger, which is a widely
accepted age cutoff point for the definition of elderly. The age
cutoff of 65 years was selected for consistency with previous
analyses of elderly patients with NSCLC.26 In addition, as a
practical consideration, using a higher age cutoff would result
in a significant imbalance between the sizes of the elderly and
nonelderly subgroups as only 266 (12.0%) patients were
older than 70 years of age. All SAEs and AESIs (all occur-
rences irrespective of severity and relationship to bevaci-
zumab) were summarized by incidence rates and 95% Pear-
son-Clopper confidence intervals (CIs).
RESULTS
Baseline Patient and Disease Characteristics
Out of the total 2212 patients in the ITT population,
623 were older than 65 years. The mean age of the ITT
population was 58.8 years (standard deviation, 10.3; range,
24–86), while the mean age in the older than 65 years
subgroup was 70.6 years (range 66–86 years). Within the
older than 65 years population, most patients were Whites
(86.2%), with stage IV disease (79.7%) and had adenocarci-
noma (83.5%). Baseline patient and disease characteristics of
elderly and younger patients are shown in Table 1. The
elderly patient cohort included smaller proportions of current
smokers than younger patients (16.9% versus 26.9%) and
patients with a good performance status (ECOG PS 0: 31.6%
versus 39.4%).
The most common comorbidity in elderly patients at
baseline was hypertension, occurring in 39.6% of elderly
versus 22.0% of younger patients. Concomitant medication at
baseline was more frequent in elderly patients than younger
patients (82.3% versus 69.9%); cardiovascular drugs were the
most common concomitant medications (48.2% in elderly
patients versus 25.1% in younger patients; Table 1), particu-
larly ACE inhibitors (18.9% versus 8.2%, respectively).
Among younger patients, the most common type of concom-
itant medication was analgesia (37.8% versus 34.7% in el-
derly patients), particularly opioids (20.5% versus 17.3% in
elderly patients). Concomitant antiplatelet therapy was used
in 11.4% of elderly and 5.2% of younger patients, and
low-dose anticoagulant therapy in 5.5% of elderly and 3.1%
of younger patients. Cisplatin doublet therapy was less fre-
quently used in elderly patients than younger patients (29.7%
versus 40.5%), but there was little difference in the use of
carboplatin doublet therapy between elderly (54.4%) and
younger (47.1%) patients.
Treatment Exposure
Median bevacizumab treatment duration was 17.3 and
22.4 weeks for elderly and younger patients, respectively. The
median number of administered bevacizumab cycles was six in
elderly patients and eight in younger patients. A greater propor-
tion of younger patients received bevacizumab maintenance
(57.8%), after four to six cycles of chemotherapy treatment, than
elderly patients (46.2%; maintenance therapy comprises contin-
ued 3-weekly cycles of bevacizumab alone until disease pro-
gression or unacceptable toxicity). Median duration of chemo-
therapy treatment and median number of cycles was 12.1 weeks
and four cycles for elderly patients, and 15.1 weeks and six
cycles for younger patients. Table 2 summarizes the chemother-
apy regimens and bevacizumab doses received by elderly and
younger patients during the study.
Safety
SAEs were reported in 45.3% and 34.7% of elderly and
younger patients, respectively, with neutropenia representing
the most frequently documented SAE in both groups (4.5% in
elderly patients and 3.5% in younger patients). Grade more
than or equal to 3 febrile neutropenia was observed in 29
patients (1.8%) in the younger subgroup and 20 patients
(3.2%) in the elderly subgroup.
AESIs were reported by 441 patients (70.8%) and 1085
patients (68.3%) in the elderly and younger patient sub-
groups, respectively. The majority of AESIs were classified
as grade less than or equal to 2 in both age cohorts (Table 3),
and the rate of grade more than or equal to 3 events was
similar for both age groups (14.8% versus 14.1% for the
elderly and younger patients, respectively). The most fre-
quently reported AESIs were bleeding events (most com-
monly epistaxis), which were reported for 238 (38.2%) el-
derly patients and 608 (38.3%) younger patients. Pulmonary
hemorrhage was reported in 52 (8.3%) elderly patients and in
134 (8.4%) younger patients. Hypertension events were re-
corded for 206 (33.1%) and 487 (30.6%) elderly and younger
patients, respectively. The only other AESI reported in more
than 5% of patients was proteinuria, and this occurred in 208
(33.4%) elderly patients and 465 (29.3%) younger patients.
AESIs were most frequently reported in association with
carboplatin doublet chemotherapy in both elderly and younger
patients (all grades 72.6 and 69.1%, respectively; grade more
than or equal to 3, 18.6 and 17.2%, respectively), followed by
nonplatinum doublet chemotherapy (all grades 57.1% versus
83.3%; grade more than or equal to 3 28.6% versus 16.7%),
cisplatin doublet chemotherapy (all grades 71.4% versus 68.5%;
grade more than or equal to 3 23.8% versus 21.4%), and
monotherapy (all grades 70.4% versus 60.0%; grade more than
or equal to 3 29.6% versus 26.7%). Bleeding events were the
most frequently reported AESIs and were generally observed
with similar frequency in elderly and younger patients in each of
the chemotherapy categories (Tables 4 and 5).
AESIs necessitating treatment interruption or discontinu-
ation are shown in Table 6. Wound-healing complications were
the most common AESI requiring treatment interruption in both
elderly and younger patients: 3 of 13 events (23.1%) and 5 of 18
events (27.8%) led to treatment interruption, respectively. Gas-
trointestinal perforation was the most frequent AESI requiring
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treatment discontinuation in both elderly and younger patients (8
of 9 events [88.9%] in elderly patients and 18 of 21 events
[85.7%] in younger patients). The majority of AESIs resolved or
improved after treatment interruption/discontinuation in both
elderly and younger patients (Table 7). Mortality rates linked to
AESIs were 2.9 and 2.5% for the elderly and younger patients,
respectively. The most common AESI causes of death were
thromboembolism, documented in 8 (1.3%) elderly and 18
(1.1%) younger patients, and bleeding in 4 (0.6%) elderly and 13
(0.8%) younger patients.
The safety profile in a post hoc analysis of patients
older than 70 versus those 70 years and younger was similar
to that reported for patients older than 65 versus 65 years or
younger (Table 8). In particular, the incidence of AESIs was
similar regardless of the cutoff used, and no new safety
signals were apparent.
Efficacy
At the time of the efficacy evaluation (July 24, 2009),
31.5% of elderly and 33.2% of younger patients were still
alive, and of these, 61.5% of elderly and 71.9% of younger
patients had progressive disease. Mean follow-up time was
12.5 months.
TABLE 1. Summary of Patient Demographics and Baseline Characteristics
Parameter
Patients 65 yr
and Younger
(n  1589)
Patients Older
than 65 yr
(n  623)
ITT Population
(n  2212)
Mean age, yr (range) 54.2 (24–65) 70.6 (66–86) 58.8 (24–86)
Male (%) 59.0 62.8 60.1
Stage (%)
IIIB 19.5 20.3 19.7
IV 80.5 79.7 80.3
ECOG PS (%)
0 39.4 31.6 37.2
1 54.7 61.3 56.6
2 5.9 7.1 6.2
Smoking status (%)
Never 29.6 32.1 30.3
Former 43.5 51.0 45.7
Current 26.9 16.9 24.1
Ethnicity (%)
Whites 78.6 86.2 80.7
Afro-Caribbean 0.8 0.3 0.6
Asian 16.7 9.6 14.7
Hispanic 2.8 3.2 2.9
Other 1.1 0.6 1.0
Metastatic disease (%)a,b
Bone 38.4 35.3 37.6
Lung 56.5 59.2 57.3
Liver 15.1 12.7 14.4
Brain 0.1 0.0 0.1
Other 41.9 38.6 40.9
Pathology (%)c
Adenocarcinoma 86.9 83.5 86.0
Bronchoalveolar carcinoma 2.3 2.8 2.4
Large cell carcinoma 6.3 8.5 6.9
Mixed cell type (50% nonsquamous) 0.4 1.2 0.6
Other 4.1 4.0 4.1
Centrally located lung tumor (%) 27.1 23.8 26.1
Tumor cavitated (%) 2.9 1.6 2.5
Receiving baseline medication (%) 69.9 82.3 73.4
Antihypertensive/cardiovascular 25.1 48.2 31.6
Anticoagulants (prophylactic) 3.1 5.5 3.8
a Percentage based on total number of patients with metastatic disease.
b Multiple metastatic sites were possible.
c Percentage based on total number of patients with tumor sample taken.
ITT, intention to treat; ECOG PS, Eastern Cooperative Oncology Group performance status.
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For elderly patients, the median TTP was 8.2 months (95%
CI, 7.5–8.7) and for younger patients was 7.6 months (95%
CI, 7.3–8.0) (Figure 1A). Median OS was 14.6 months for
both elderly (95% CI, 13.0–15.4) and younger patients (95%
CI, 13.7–15.7) (Figure 1B). ORR was 49.3% and 52.4% for
elderly and younger patients, respectively, and complete
response was documented for 2.7% of elderly and 3.4% of
younger patients. DCR (ORR  stable disease) was 89.3%
for elderly patients and 88.4% for younger patients. Similar
efficacy outcomes were seen in a post hoc analysis of patients
older than 70 years versus those 70 years or younger (Table
8). Median OS was the same in both the older than 70 years
and 70 years or younger groups (14.6 months), while median
TTP was slightly higher in the older than 70 years group (8.6
months) versus the 70 years or younger group (7.7 months).
DISCUSSION
Although mortality attributed to lung cancer has de-
creased in younger patients (50 years or younger), increasing
lung cancer mortality rates have been documented for older
patients (older than 70 years).27 This finding may be attrib-
utable, at least in part, to lower use of any treatment, partic-
ularly chemotherapy, in elderly compared with younger pa-
tients; little more than 20% of elderly patients with advanced
lung cancer ever receive chemotherapy.9–11,28
It is commonly perceived that outcomes observed in
clinical trials may not be achieved in a real-world setting
because patients may be older and have less favorable health
characteristics. Consequently, physicians may be wary of
using chemotherapy in populations that are under-represented
in clinical trials. Indeed, despite the increasing population of
elderly patients with cancer, their representation in clinical
trials evaluating new anticancer agents remains poor.29–31
There may also be a belief among physicians that
antiangiogenic agents may be less well tolerated by elderly
patients and they may consequently be more inclined to
discontinue treatment in elderly patients at earlier grades of
toxicity than they would in younger patients.
The SAiL study of bevacizumab in combination with
chemotherapy followed by bevacizumab monotherapy for the
management of patients with advanced NSCLC aimed to
address questions on the utility of this regimen in routine
clinical practice. This analysis of the SAiL study was under-
taken to determine the effect of age on outcomes of bevaci-
zumab in combination with chemotherapy followed by bevaci-
zumab monotherapy, including patients receiving concomitant
medications and those with an ECOG PS of 2. Given the
under-representation of patients older than 65 years in the
clinical trials that establish clinical practice for patients with
advanced NSCLC, 65 years of age was selected as the
criterion for the subgroup analysis by age in the SAiL study.
The definition of elderly as older than 65 years used in this
preplanned analysis has previously been used in the oncology
literature,24 although a cutoff age of older than 70 years is
sometimes used.32 When the SAiL study started, both age
cutoffs were considered to be acceptable definitions of el-
derly. The use of 65 years as the definition of elderly in our
preplanned analysis allowed for sufficient patient numbers to
be included in the elderly subgroup to allow meaningful
TABLE 2. Summary of Treatment Regimens
Treatment Regimen,
n (%)
Patients 65 yr
and Younger
(n  1589)
Patients Older
than 65 yr
(n  623)
ITT Population
(n  2212)
Platinum doublet 1392 (88) 524 (84) 1916 (87)
Cisplatin doublet 644 (41) 185 (30) 829 (37)
Carboplatin doublet 748 (47) 339 (54) 1087 (49)
Nonplatinum doublet 6 (1) 7 (1) 13 (1)
Single agenta 15 (1) 27 (4) 42 (2)
Otherb 8 (1) 2 (1) 10 (1)
Bevacizumab
7.5 mg/kg 181 (11) 79 (13) 260 (12)
15 mg/kg 1403 (88) 541 (87) 1944 (88)
Switched dose 5 (1) 3 (1) 8 (1)
a Carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel, pemetrexed, and vinore-
lbine.
b Triplet and quadruplet chemotherapy regimens.
ITT, intention to treat; NA, not available.
TABLE 3. AEs of Special Interest
Patients with at Least
One Event, n (%)
Patients 65 yr and Younger (n  1589) Patients Older than 65 yr (n  623)
Grade 1–2 Grade 3 Grade 4 Grade 5 Grade 1–2 Grade 3 Grade 4 Grade 5
Overall bleeding 573 (36.1) 31 (2.0) 3 (0.2) 13 (0.8) 218 (35.0) 25 (4.0) 5 (0.8) 4 (0.6)
Epistaxis 426 (26.8) 12 (0.8) 0 0 156 (25.0) 14 (2.2) 3 (0.5) 0
Pulmonary hemorrhagea 124 (7.8) 4 (0.3) 0 7 (0.4) 49 (7.9) 1 (0.2) 2 (0.3) 1 (0.2)
CNS bleedingb 3 (0.2) 1 (0.1) 0 0 2 (0.3) 0 0 1 (0.2)
Hypertension 421 (26.5) 86 (5.4) 5 (0.3) 0 180 (28.9) 34 (5.5) 1 (0.2) 0
Proteinuria 433 (27.2) 41 (2.6) 6 (0.4) 0 194 (31.1) 15 (2.4) 5 (0.8) 0
Thromboembolism 77 (4.8) 79 (5.0) 39 (2.5) 18 (1.1) 38 (6.1) 25 (4.0) 15 (2.4) 8 (1.3)
Gastrointestinal perforation 3 (0.2) 10 (0.6) 4 (0.3) 4 (0.3) 0 3 (0.5) 2 (0.3) 4 (0.6)
Wound-healing complications 14 (0.9) 1 (0.1) 1 (0.1) 0 10 (1.6) 0 0 0
Congestive heart failure 1 (0.1) 2 (0.1) 0 4 (0.3) 5 (0.8) 1 (0.2) 2 (0.3) 2 (0.3)
a Pulmonary hemorrhage/hemoptysis.
b Cerebral hemorrhage/hematoma.
AEs, adverse events; CNS, central nervous system.
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comparison with the younger patients. Our post hoc analysis
using a cutoff age of 70 years showed similar efficacy and
safety to the 65-year-old analysis.
As expected, elderly patients tended to have a poorer
performance status than their younger counterparts, and comor-
bidities were more common in the elderly subgroup, notably
hypertension. These findings are consistent with previous stud-
ies.13 Furthermore, the use of concomitant medication was
substantially greater in elderly than in younger patients; this was
largely due to greater use of cardiovascular medications.
TABLE 4. Incidence of AEs of Special Interest (All Grades) By Chemotherapy Regimen—Younger Patients
Patients with
at Least One
Event, n (%)
Patients 65 yr and Younger (n  1589)
Carboplatin
Doublets
n  748
Cisplatin
Doublets
n  644
Nonplatinum
Doublets
n  6
Monotherapy
n  15
Other
Combinations
n  8
Switched
Chemotherapy
n  168
All
Grades
Grade
>3
All
Grades
Grade
>3
All
Grades
Grade
>3
All
Grades
Grade
>3
All
Grades
Grade
>3
All
Grades
Grade
>3
AESI (any grade) 517 (69.1) 441 (68.5) 5 (83.3) 9 (60.0) 0 113 (67.3)
Overall bleeding 307 (41.0) 20 (2.7) 226 (35.1) 21 (3.3) 2 (33.3) 1 (16.7) 4 (26.7) 1 (6.7) 0 0 69 (41.1) 4 (2.4)
Epistaxis 217 (29.0) 3 (0.4) 164 (25.5) 8 (1.2) 1 (16.7) 0 2 (13.3) 0 0 0 50 (29.8) 1 (0.6)
Pulmonary
hemorrhagea
81 (10.8) 5 (0.7) 44 (6.8) 4 (0.6) 0 0 2 (13.3) 1 (6.7) 0 0 7 (4.2) 1 (0.6)
CNS bleedingb 2 (0.3) 0 1 (0.2) 1 (0.2) 0 0 0 0 0 0 1 (0.6) 0
Hypertension 199 (26.6) 30 (4.0) 232 (36.0) 49 (7.6) 0 0 5 (33.3) 1 (6.7) 0 0 51 (30.4) 10 (6.0)
Proteinuria 238 (31.8) 26 (3.5) 173 (26.9) 13 (2.0) 3 (50.0) 0 3 (20.0) 1 (6.7) 0 0 48 (28.6) 7 (4.2)
Thromboembolism 70 (9.4) 48 (6.4) 100 (15.5) 64 (9.9) 0 0 1 (6.7) 0 0 0 25 (14.9) 14 (8.3)
Gastrointestinal
perforation
11 (1.5) 11 (1.5) 5 (0.8) 4 (0.6) 0 0 0 0 0 0 5 (3.0) 3 (1.8)
Wound-healing
complications
6 (0.8) 1 (0.1) 8 (1.2) 1 (0.2) 1 (16.7) 0 0 0 0 0 1 (0.6) 0
Congestive heart
failure
4 (0.5) 3 (0.4) 2 (0.3) 2 (0.3) 0 0 1 (6.7) 1 (6.7) 0 0 0 0
a Pulmonary hemorrhage/hemoptysis.
b Cerebral hemorrhage/hematoma.
AEs, adverse events; AESI, adverse events of special interest; CNS, central nervous system.
TABLE 5. Incidence of AEs of Special Interest (All Grades) by Chemotherapy Regimen—Elderly Patients
Patients with
at Least One
Event, n (%)
Patients Older than 65 yr (n  623)
Carboplatin
Doublets
n  339
Cisplatin
Doublets
n  185
Nonplatinum
Doublets
n  7
Monotherapy
n  27
Other
Combinations
n  2
Switched
Chemotherapy
n  63
All
Grades
Grade
>3
All
Grades
Grade
>3
All
Grades
Grade
>3
All
Grades
Grade
>3
All
Grades
Grade
>3
All
Grades
Grade
>3
AESI (any grade) 246 (72.6) 132 (71.4) 4 (57.1) 19 (70.4) 1 (50.0) 39 (61.9)
Overall bleeding 143 (42.2) 19 (5.6) 65 (35.1) 10 (5.4) 3 (42.9) 1 (14.3) 7 (25.9) 1 (3.7) 0 0 20 (31.7) 2 (3.2)
Epistaxis 101 (29.8) 10 (2.9) 48 (25.9) 4 (2.2) 2 (28.6) 0 3 (11.1) 1 (3.7) 0 0 13 (20.6) 1 (1.6)
Pulmonary
hemorrhagea
32 (9.4) 3 (0.9) 12 (6.5) 1 (0.5) 0 0 3 (11.1) 0 0 0 5 (7.9) 0
CNS bleedingb 2 (0.6) 0 0 0 1 (14.3) 1 (14.3) 0 0 0 0 0 0
Hypertension 111 (32.7) 13 (3.8) 63 (34.1) 12 (6.5) 2 (28.6) 1 (14.3) 6 (22.2) 2 (7.4) 1 (50.0) 1 (50.0) 23 (36.5) 6 (9.5)
Proteinuria 117 (34.5) 10 (2.9) 59 (31.9) 4 (2.2) 0 0 10 (37.0) 1 (3.7) 1 (50.0) 0 21 (33.3) 5 (7.9)
Thromboembolism 34 (10.0) 19 (5.6) 37 (20.0) 22 (11.9) 0 0 2 (7.4) 2 (7.4) 0 0 6 (9.5) 3 (4.8)
Gastrointestinal
perforation
5 (1.5) 5 (1.5) 3 (1.6) 3 (1.6) 0 0 0 0 0 0 1 (1.6) 1 (1.6)
Wound-healing
complications
8 (2.4) 0 1 (0.5) 0 0 0 1 (3.7) 0 0 0 0 0
Congestive heart
failure
2 (0.6) 1 (0.3) 4 (2.2) 2 (1.1) 0 0 3 (11.1) 2 (7.4) 0 0 1 (1.6) 0
a Pulmonary hemorrhage/hemoptysis.
b Cerebral hemorrhage/hematoma.
AEs, adverse events; AESI, adverse events of special interest; CNS, central nervous system.
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It is perhaps then not surprising that the median number
of cycles, duration of chemotherapy, and total time on bev-
acizumab in this study were shorter in elderly than in younger
patients. However, the rates of AESIs were comparable in
elderly and younger patients and the majority of events were
grade less than or equal to 2 in both cohorts. There were
remarkable similarities between the two age cohorts with
respect to specific AESIs, including bleeding, hypertension,
TABLE 6. AEs of Special Interest Leading to Temporary Interruption or Permanent
Discontinuation of Bevacizumab
AEs, n (%)a
Patients 65 yr and Younger
(n  1589)
Patients Older than 65 yr
(n  623)
Temporary
Interruption
Permanent
Discontinuation
Temporary
Interruption
Permanent
Discontinuation
Overall bleeding 18 (1.1) 78 (4.9) 10 (1.6) 32 (5.1)
Hypertension 55 (3.5) 23 (1.4) 17 (2.7) 17 (2.7)
Proteinuria 25 (1.6) 19 (1.2) 13 (2.1) 12 (1.9)
Thromboembolism 26 (1.6) 97 (6.1) 8 (1.3) 43 (6.9)
Gastrointestinal perforation 0 18 (1.1) 0 8 (1.3)
Wound-healing complications 5 (0.3) 1 (0.1) 3 (0.5) 0
Congestive heart failure 1 (0.1) 4 (0.3) 1 (0.2) 5 (0.8)
a Percentages are based on total number of patients within each age category.
AEs, adverse events.
TABLE 7. Outcomes of AEs of Special Interest after Treatment Interruption/Discontinuation
Patients 65 yr and Younger (n  1589) Patients Older than 65 yr (n  623)
AEs, n (%)a n Resolved Improved Persistent Led to Death n Resolved Improved Persistent Led to Death
Overall bleeding 976 833 (85.3) 25 (2.6) 105 (10.8) 13 (1.3) 371 321 (86.5) 14 (3.8) 32 (8.6) 4 (1.1)
Hypertension 727 548 (75.4) 63 (8.7) 116 (16.0) 0 298 230 (77.2) 31 (10.4) 37 (12.4) 0
Proteinuria 734 502 (68.4) 71 (9.7) 161 (21.9) 0 312 215 (68.9) 31 (9.9) 66 (21.2) 0
Thromboembolism 233 108 (46.4) 40 (17.2) 67 (28.8) 18 (7.7) 91 48 (52.7) 17 (18.7) 18 (19.8) 8 (8.8)
Gastrointestinal perforation 21 13 (61.9) 3 (14.3) 1 (4.8) 4 (19.0) 9 5 (55.6) 0 0 4 (44.4)
Wound-healing complications 18 12 (66.7) 1 (5.6) 5 (27.8) 0 13 10 (76.9) 1 (7.7) 2 (15.4) 0
Congestive heart failure 7 1 (14.3) 1 (14.3) 1 (14.3) 4 (57.1) 11 5 (45.5) 1 (9.1) 3 (27.3) 2 (18.2)
a Percentages are based on total number of AEs within each AE category.
AEs, adverse events.
TABLE 8. Comparison of Efficacy and Safety Outcomes for Different Elderly Cutoffs (Older than 65 yr Versus Older than 70 yr)
Efficacy Outcomes
65 yr or Younger
(n  1589)
Older than 65 yr
(n  623)
70 yr or Younger
(n  1946)
Older than 70 yr
(n  266)
TTP, months (95% CI) 7.6 (7.38.0) 8.2 (7.58.7) 7.7 (7.48.1) 8.6 (7.39.2)
OS, months (95% CI) 14.6 (13.715.7) 14.6 (13.015.4) 14.6 (13.815.4) 14.6 (11.017.1)
RR (%) 52 49 52 49
DCR (%) 88 89 88 90
65 yr or Younger Older than 65 yr 70 yr or Younger Older than 70 yr
AESIs (%) Gr 3 Gr 4 Gr 5 Gr 3 Gr 4 Gr 5 Gr 3 Gr 4 Gr 5 Gr 3 Gr 4 Gr 5
Overall bleeding 2.0 0.2 0.8 4.0 0.8 0.6 2.4 0.3 0.8 3.4 1.1 0.8
Epistaxis 0.8 0 0 2.2 0.5 0 1.2 0.1 0 1.1 0.8 0
Pulmonary hemorrhage 0.3 0 0.4 0.2 0.3 0.2 0.1 0 0.1 0 0.4 0
CNS bleeding 0.1 0 0 0 0 0.2 0.1 0 0.1 0 0 0
Hypertension 5.4 0.3 0 5.5 0.2 0 5.5 0.2 0 4.5 0 0
Proteinuria 2.6 0.4 0 2.4 0.8 0 2.7 0.5 0 1.5 0.4 0
Thromboembolism 5.0 2.5 1.1 4.0 2.4 1.3 4.8 2.5 1.2 4.1 2.3 0.8
Gastrointestinal perforation 0.6 0.3 0.3 0.5 0.3 0.6 0.7 0.3 0.4 0 0.4 0.4
Wound-healing complications 0.1 0.1 0 0 0 0 0.1 0.1 0 0 0 0
Congestive heart failure 0.1 0 0.3 0.2 0.3 0.3 0.2 0.1 0.3 0 0.4 0.4
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proteinuria, and thromboembolism. Furthermore, AESIs re-
quiring treatment interruption or discontinuation occurred
with similar frequency in elderly and younger patients, and
the majority of AEs resolved or improved during the study.
Mortality attributed to treatment-related AESIs was similarly
low in both age cohorts. No effect of age was apparent with
regard to the rates of AESIs across patients who received
different chemotherapy regimens; admittedly some of the
chemotherapy regimens were only given in small numbers.
The AVAiL and ECOG 4599 phase III studies evalu-
ated first-line bevacizumab with gemcitabine-cisplatin and
paclitaxel-carboplatin, respectively. Both trials met their pri-
mary end points. AVAiL demonstrated significant improve-
ments in PFS21,22 and ECOG 4599 demonstrated a significant
OS benefit in patients receiving bevacizumab.20 In the SAiL
study, there was an absence of a notable effect of age on the
tolerability of bevacizumab-based therapy which is consistent
with the findings of the AVAiL study: a retrospective sub-
group analysis of 304 elderly (65 years or older) patients in
AVAiL identified no new safety signals in elderly patients
and similar rates of grade more than or equal to 3 toxicities
between treatment arms (bevacizumab 7.5 mg/kg, 15 mg/kg,
and placebo: 84, 80, and 80%, respectively).26 However, a
retrospective subgroup analysis of older (70 years or older)
patients (n 224) in the ECOG 4599 study demonstrated that
the addition of bevacizumab to chemotherapy led to a signif-
icant increase in the incidence of grade more than or equal to
3 toxicities versus paclitaxel-carboplatin alone (87% versus
61%; p  0.001); seven treatment-related deaths occurred
among elderly patients who received bevacizumab versus two
deaths in the chemotherapy alone arm.33 Furthermore, grade
more than or equal to 3 neutropenia, bleeding, and proteinuria
were reported more frequently with bevacizumab in elderly
than younger patients.33 The discrepant age effects in the
ECOG trial compared with the AVAiL and SAiL trials with
respect to toxicity may be due, at least in part, to a difference
between the age criterion used in the analyses (65 years in
AVAiL and SAiL and 70 years in the ECOG 4599 study) and
also in the proportions of patients who were very elderly (i.e.,
older than 75 years) in the different arms. The difference in
the chemotherapy backbone used could also account for these
differences, but the broad patient selection criteria and diver-
sity of chemotherapies in SAiL suggest that this is less likely
to be the case. In this subgroup analysis of the SAiL study,
response rates were similar in elderly and younger patients, as
were disease control rates, TTP, and OS. These findings are
compatible with the retrospective analyses of AVAiL and
ECOG 4599 showing that the PFS benefit with bevacizumab
is maintained in elderly patients26 and age is not a negative
prognostic factor for survival (p 0.34).33 Median OS results
for bevacizumab eligible patients included in SAiL (14.6
months),23 are similar to survival results for bevacizumab-
treated patients in more rigorously controlled phase III trials
such as AVAiL (13.6 and 13.4 months with bevacizumab 7.5
and 15 mg/kg, respectively)22 and ECOG 4599 (12.3
months).20
Given the large number of older patients enrolled in the
SAiL study, this dataset provides a valuable resource for
evaluating safety, tolerability, and efficacy of bevacizumab-
based therapy in the elderly and is in accord with the findings
for elderly patients from the AVAiL trial in terms of efficacy
and lack of any additional toxicities being reported. This
analysis according to age provides reassurance that elderly
patients can tolerate first-line bevacizumab in combination
with appropriate chemotherapy regimens and derive a similar
benefit as younger patients.
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